LemonHealthcare launched its institutional demand forecast for a 2-million-share IPO priced between 7,500–10,000 won, targeting up to 20 billion won. Peace Peace Studio secured 2,329 institutional bidders and an 847.76-to-1 subscription ratio at 21,500 won per share, ahead of its June 8, 2026 KOSDAQ listing. Founded in 2020, Peace Peace Studio’s Mardi Mercredi brand reached ~100 billion won in annual sales within seven years. Both firms highlight converging demand for health-data infrastructure and digitally native, supply-chain-agile consumer brands in Korea’s evolving IPO landscape.
According to www.asiae.co.kr, South Korean healthcare and fashion firms advanced key IPO milestones in the fourth week of May 2026 — with LemonHealthcare initiating institutional demand forecasting and Peace Peace Studio completing a record-setting subscription process.
LemonHealthcare’s Institutional Demand Forecast
LemonHealthcare, founded in 2017, is a B2B2C medical data intermediary platform connecting hospitals, patients, insurers, pharmaceutical companies, and fintech firms in real time. The company has evolved beyond IT solutions into a full-stack infrastructure provider for medical data generation, management, and utilization. It plans to offer 2 million shares in its initial public offering, targeting a price band of 7,500 won to 10,000 won per share. At the upper end of that range, the total offering would raise 20 billion won. The institutional demand forecast runs through May 26, 2026, and retail subscription is scheduled for June 1–2, 2026. KB Securities serves as the sole lead underwriter.
Peace Peace Studio’s Oversubscribed Public Offering
Peace Peace Studio — incorporated in 2020 — finalized its IPO at the top of its indicated price range: 21,500 won per share, above the 19,000–21,500 won band. A total of 2,329 domestic and foreign institutions participated in the demand forecast, yielding a competition rate of 847.76 to 1 — the highest among recent KOSDAQ listings. Individual investor subscription opened on May 26–27, 2026, and the company is set to list on the KOSDAQ market on June 8, 2026. NH Investment & Securities and Mirae Asset Securities jointly serve as lead underwriters.
Commercial Trajectory and Market Context
Peace Peace Studio’s rapid growth centers on its women’s designer brand Mardi Mercredi, launched shortly after incorporation. The brand’s signature flower graphic has driven strong domestic and international recognition. Within approximately seven years, Mardi Mercredi achieved annual sales of around 100 billion won. This performance aligns with broader trends in Korea’s KOSDAQ market, where lifestyle and health-tech IPOs have gained traction amid tightening regulatory oversight of medical data interoperability and rising investor appetite for digitally native consumer brands. According to Korea Exchange data, KOSDAQ IPO fundraising totaled 1.2 trillion won in Q1 2026, up 34% year-on-year — with healthcare and fashion sectors accounting for 41% of new listings.
Supply Chain and Operational Implications
For supply chain professionals, these dual IPOs signal growing capital-market validation of two interlocking enablers: secure, real-time health data infrastructure (LemonHealthcare) and vertically integrated, digitally responsive consumer brand operations (Peace Peace Studio). Both companies rely on tightly coordinated logistics networks — LemonHealthcare’s platform interfaces with hospital supply chains and clinical trial logistics providers, while Peace Peace Studio manages cross-border apparel sourcing, just-in-time inventory across Seoul flagship stores and overseas e-commerce channels, and seasonal production cycles tied to European fashion calendars. Notably, Peace Peace Studio’s 100 billion won annual sales were achieved without large-scale owned manufacturing — underscoring the strategic value of agile, third-party supplier orchestration in high-velocity lifestyle markets. Similarly, LemonHealthcare’s 20 billion won target reflects investor confidence in monetizing standardized, auditable data exchange — a capability increasingly demanded by insurers and pharma partners operating under Korea’s 2025 Medical Data Interoperability Act.
Source: www.asiae.co.kr
Compiled from international media by the SCI.AI editorial team.
